구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | AVL (AAV8hAAT, AAV8hAAT(AVL)) National Heart, Lung, and Blood In…·Alpha 1-Antitrypsin Deficiency 10 trials |
|---|---|
Overview Program | AAV8hAAT(AVL) |
Overview Company | National Heart, Lung, and Blood Institute (NHLBI) |
Overview Modality | CGT |
Overview Target | Alpha 1-Antitrypsin Deficiency |
Overview Indication | Alpha 1-Antitrypsin Deficiency |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting cilium-based Hedgehog signaling |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse, xenografts, few model, Importantly |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, xenografts, few model, Importantly |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | thrombocytopenia (46 [10%]), and hypokalaemia (35 [7%]), and treatment-related serious adverse e |
Clinical Safety signal | thrombocytopenia (46 [10%]), and hypokalaemia (35 [7%]), and treatment-related serious adverse e |
Clinical Program phase | PHASE_1 |
Preclinical Animal (cat.) | Rat |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | AVL (AAV8hAAT, AAV8hAAT(AVL)) National Heart, Lung, and Blood In…·Alpha 1-Antitrypsin Deficiency 10 trials |
|---|---|
Overview Program | AAV8hAAT(AVL) |
Overview Company | National Heart, Lung, and Blood Institute (NHLBI) |
Overview Modality | CGT |
Overview Target | Alpha 1-Antitrypsin Deficiency |
Overview Indication | Alpha 1-Antitrypsin Deficiency |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting cilium-based Hedgehog signaling |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse, xenografts, few model, Importantly |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, xenografts, few model, Importantly |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | thrombocytopenia (46 [10%]), and hypokalaemia (35 [7%]), and treatment-related serious adverse e |
Clinical Safety signal | thrombocytopenia (46 [10%]), and hypokalaemia (35 [7%]), and treatment-related serious adverse e |
Clinical Program phase | PHASE_1 |
Preclinical Animal (cat.) | Rat |
추천 비교
추천 비교